Pharmacogénétique, réponse et toxicité de la chimiothérapie 105
of 5-Fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD
deficiency. Clin Canc Res 7: 1149-53
23. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, et al. (
l l 2002) Increased risk of grade IV
neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase
deficiency: high prevalence of the IVS14+1G>A mutation. Int J Cancer 101: 253-8
24. Van Kuilenburg ABP, Abreu R, Van Gennip A (2003) Pharmacogenetic and clinical aspects
of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 40: 41-5
25. Johnson MR, Yan J, Shao L, et al. (1997) Semi-automated radioassay for determination
of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD
deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr 696: 183-91
26. Fleming R, Milano G, Thyss A, et al. (1992) Correlation between dihydropyrimidine
l l
dehydrogenase activity in peripheral mononuclear cells and systemic clearance of
fluorouracil in cancer patients. Cancer Res 52: 2899-902
27. Etienne MC, Lagrange JL, Dassonville O, et al. (1994) Population study of
l l
dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248-53
28. Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human
peripheral blood mononuclear cells and liver: population characteristics, newly identified
deficient patients, and clinical implication in -fluorouracil chemotherapy. Cancer Res 53:
5433-8
29. Seck K, Riemer S, Kates R, et al. (2005) Analysis of the
l l
DPYD gene implicated in
D
5-fluorouracil catabolism in a cohort of caucasian individuals. Clin Cancer Res 11: 5886-92
30. Johnson MR, Wang K, Smith JB, et al. (2000) Quantitation of dihydropyrimidine
dehydrogenase expression by real-time reverse transcription polymerase chain reaction.
Anal Biochem 278: 175-84
31. Boisdron-Celle M, Remaud G, Traore S, et al. (2007) 5-Fluorouracil-related severe toxicity:
l l
a comparison of different methods for the pretherapeutic detection of dihydropyrimidine
dehydrogenase deficiency. Cancer letters 249: 271-82
32. Van Gennip AH, Van Bree-Blom EJ, Wadman SK, et al. (1982) HPLC of urinary pyrimidines
l l
for the evaluation of primary and secondary abnormalities of pyrimidine metabolism. In:
Hawk GL, ed. Biological biomedical applications of liquid chromatography.III. New York
and Basel, Marcel Dekker Inc, p 285-96
33. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. (1999) Correlation between uracil
and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and
tolerance in patients with advanced colorectal cancer: A potential interest for predicting
5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17(4): 1105-10
34. Zhou, ZW, Wang GQ, Wan DS (2007) The dihydrouracil/uracil ratios in plasma and
toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Chemotherapy 53(2): 127-31
35. Morel A, Boisdron-Celle M, Fey L, et al. (2007)
l l
Identification of a novel mutation in
the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following
5-fluorouracil administration and the determination of its frequency in a population of
500 patients with colorectal carcinoma. Clin Biochem 40(1-2): 11-7
36. Boisdron Celle M, Capitain O, Metges JP, et al. l l (2012) Severe Fluoropyrimidines toxicities:
a simple and effective way to avoid them. Screen effectively for DPD deficiencies. ESMO
GI, Barcelone, 27-29 juin
37. Remaud G, Boisdron-Celle M, Hameline C, et al. (2005) An accurate Dihydrouracil/
l l
Uracil determination using improved High Performance Liquid Chromatography method
for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B
823(2): 98-107
38. Traoré S, Boisdron-Celle M, Hunault G, et al. l l (2012) DPD deficiency: Medico-economic
evaluation of pre-treatment screening of 5-FU toxicity. ASCO GI, San Francisco, 19-21
janvier
of 5-Fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD
deficiency. Clin Canc Res 7: 1149-53
23. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, et al. (
l l 2002) Increased risk of grade IV
neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase
deficiency: high prevalence of the IVS14+1G>A mutation. Int J Cancer 101: 253-8
24. Van Kuilenburg ABP, Abreu R, Van Gennip A (2003) Pharmacogenetic and clinical aspects
of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 40: 41-5
25. Johnson MR, Yan J, Shao L, et al. (1997) Semi-automated radioassay for determination
of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD
deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr 696: 183-91
26. Fleming R, Milano G, Thyss A, et al. (1992) Correlation between dihydropyrimidine
l l
dehydrogenase activity in peripheral mononuclear cells and systemic clearance of
fluorouracil in cancer patients. Cancer Res 52: 2899-902
27. Etienne MC, Lagrange JL, Dassonville O, et al. (1994) Population study of
l l
dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248-53
28. Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human
peripheral blood mononuclear cells and liver: population characteristics, newly identified
deficient patients, and clinical implication in -fluorouracil chemotherapy. Cancer Res 53:
5433-8
29. Seck K, Riemer S, Kates R, et al. (2005) Analysis of the
l l
DPYD gene implicated in
D
5-fluorouracil catabolism in a cohort of caucasian individuals. Clin Cancer Res 11: 5886-92
30. Johnson MR, Wang K, Smith JB, et al. (2000) Quantitation of dihydropyrimidine
dehydrogenase expression by real-time reverse transcription polymerase chain reaction.
Anal Biochem 278: 175-84
31. Boisdron-Celle M, Remaud G, Traore S, et al. (2007) 5-Fluorouracil-related severe toxicity:
l l
a comparison of different methods for the pretherapeutic detection of dihydropyrimidine
dehydrogenase deficiency. Cancer letters 249: 271-82
32. Van Gennip AH, Van Bree-Blom EJ, Wadman SK, et al. (1982) HPLC of urinary pyrimidines
l l
for the evaluation of primary and secondary abnormalities of pyrimidine metabolism. In:
Hawk GL, ed. Biological biomedical applications of liquid chromatography.III. New York
and Basel, Marcel Dekker Inc, p 285-96
33. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. (1999) Correlation between uracil
and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and
tolerance in patients with advanced colorectal cancer: A potential interest for predicting
5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17(4): 1105-10
34. Zhou, ZW, Wang GQ, Wan DS (2007) The dihydrouracil/uracil ratios in plasma and
toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Chemotherapy 53(2): 127-31
35. Morel A, Boisdron-Celle M, Fey L, et al. (2007)
l l
Identification of a novel mutation in
the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following
5-fluorouracil administration and the determination of its frequency in a population of
500 patients with colorectal carcinoma. Clin Biochem 40(1-2): 11-7
36. Boisdron Celle M, Capitain O, Metges JP, et al. l l (2012) Severe Fluoropyrimidines toxicities:
a simple and effective way to avoid them. Screen effectively for DPD deficiencies. ESMO
GI, Barcelone, 27-29 juin
37. Remaud G, Boisdron-Celle M, Hameline C, et al. (2005) An accurate Dihydrouracil/
l l
Uracil determination using improved High Performance Liquid Chromatography method
for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B
823(2): 98-107
38. Traoré S, Boisdron-Celle M, Hunault G, et al. l l (2012) DPD deficiency: Medico-economic
evaluation of pre-treatment screening of 5-FU toxicity. ASCO GI, San Francisco, 19-21
janvier